Dynavax Awarded Grant To Support Development Of TLR Inhibitors In Skin Diseases

Main Category: Dermatology
Article Date: 15 May 2009 - 1:00 PDT

email to a friend   printer friendly   opinions  

Dynavax Technologies Corporation (Nasdaq:DVAX) announced the award of a Small Business Innovation Research (SBIR) grant by the National Institute of Allergy and Infectious Diseases (NIAID). This grant will support the preclinical development of Dynavax's first-in-class oligonucleotide-based Toll-like Receptor (TLR) inhibitors for use in inflammatory skin diseases such as psoriasis, cutaneous lupus, and dermatomyositis. This new two-year $700,000 grant is in addition to a $1.8 million grant awarded in 2008.

"In addition to validating our proprietary technology, this new grant supports the preclinical studies for our TLR inhibitors, which represent a novel therapeutic approach for the treatment of inflammatory skin disorders," commented Robert L. Coffman, Ph.D., Vice President and Chief Scientific Officer of Dynavax Technologies. "Grant funding and partnerships with leading pharmaceutical companies help us advance the development of our TLR-based products targeting significant unmet medical needs."

For more information about Dynavax's TLR inhibitor program, visit here.

Source
Dynavax Technologies Corporation

• Additional
• References
• Citations